Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years
Epidemiology, detection, and management of NAFLD: a Latin American perspective
Optimisation of supportive, palliative and end of life care
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma
What is required to advance data ethics, data sharing, and Open Science across LMICs
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma
Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission